IO Biotech, Inc. (IOBT)

Market Cap	97.50M
Revenue (ttm)	n/a
Net Income (ttm)	-86.08M
Shares Out	65.88M
EPS (ttm)	-1.98
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	38,770
Open	1.530
Previous Close	1.530
Day's Range	1.480 - 1.580
52-Week Range	0.816 - 2.640
Beta	0.50
Analysts	Strong Buy
Price Target	8.33 (+444.44%)
Earnings Date	May 13, 2024

About IOBT

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that c...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 5, 2021
• Employees: 68
• Stock Exchange: NASDAQ
• Ticker Symbol: IOBT

Analyst Forecast

According to 3 analysts, the average rating for IOBT stock is "Strong Buy." The 12-month stock price forecast is $8.33, which is an increase of 444.44% from the latest price.

Price Target

$8.33

(444.44% upside)

Analyst Consensus: Strong Buy